The epithelial-mesenchymal transition (EMT) has recently been linked to stem cell phenotype 1,2 . However, the molecular mechanism underlying EMT and regulation of stemness remains elusive. Here, using genomic approaches, we show that tumour suppressor p53 has a role in regulating both EMT and EMT-associated stem cell properties through transcriptional activation of the microRNA miR-200c. p53 transactivates miR-200c through direct binding to the miR-200c promoter. Loss of p53 in mammary epithelial cells leads to decreased expression of miR-200c and activates the EMT programme, accompanied by an increased mammary stem cell population. Re-expressing miR-200c suppresses genes that mediate EMT and stemness properties 3, 4 and thereby reverts the mesenchymal and stem-cell-like phenotype caused by loss of p53 to a differentiated epithelial cell phenotype. Furthermore, loss of p53 correlates with a decrease in the level of miR-200c, but an increase in the expression of EMT and stemness markers, and development of a high tumour grade in a cohort of breast tumours. This study elucidates a role for p53 in regulating EMT-MET (mesenchymal-epithelial transition) and stemness or differentiation plasticity, and reveals a potential therapeutic implication to suppress EMT-associated cancer stem cells through activation of the p53-miR-200c pathway.
The epithelial-mesenchymal transition (EMT) has recently been linked to stem cell phenotype 1, 2 . However, the molecular mechanism underlying EMT and regulation of stemness remains elusive. Here, using genomic approaches, we show that tumour suppressor p53 has a role in regulating both EMT and EMT-associated stem cell properties through transcriptional activation of the microRNA miR-200c. p53 transactivates miR-200c through direct binding to the miR-200c promoter. Loss of p53 in mammary epithelial cells leads to decreased expression of miR-200c and activates the EMT programme, accompanied by an increased mammary stem cell population. Re-expressing miR-200c suppresses genes that mediate EMT and stemness properties 3, 4 and thereby reverts the mesenchymal and stem-cell-like phenotype caused by loss of p53 to a differentiated epithelial cell phenotype. Furthermore, loss of p53 correlates with a decrease in the level of miR-200c, but an increase in the expression of EMT and stemness markers, and development of a high tumour grade in a cohort of breast tumours. This study elucidates a role for p53 in regulating EMT-MET (mesenchymal-epithelial transition) and stemness or differentiation plasticity, and reveals a potential therapeutic implication to suppress EMT-associated cancer stem cells through activation of the p53-miR-200c pathway.
The EMT and the reverse process, MET, are key programmes in regulating embryogenesis 5 . There is evidence to suggest that aberrant EMT activation also contributes to cancer progression and metastasis 2 . Recent findings further illustrate a link between EMT and the gain of stem cell properties in normal and neoplastic cell populations 1, 2 . MicroRNAs (miRNAs), the small non-coding RNA molecules that suppress gene expression by interacting with the 3ʹ untranslated regions (3ʹ UTRs) of target mRNAs, have also been linked to EMT and cancer 3 . Notably, miR-200c was shown to regulate EMT by inhibiting ZEB1/2, transcriptional repressors of E-cadherin, a known epithelial cell marker. Reports have also indicated that miR-200c is downregulated in normal stem cell and neoplastic stem cell population as it suppresses BMI1, a Polycomb protein that is involved in the maintenance of stemness properties 3, 4 . All these results suggest that miR-200c may have an integral role in modulating EMT and stem cell phenotype.
Despite the efforts in studying EMT and stem cell properties, regulation of the plasticity of EMT-stemness is not clear and the molecular mechanisms that regulate miR-200c or other stemness-related miRNAs is also largely unknown. Thus, we first attempted to investigate miRNA expression profiles in CD24 -CD44 + (stem) and non-CD24 -CD44 + (non-stem) cell populations isolated from primary human mammalian epithelial cells (HMECs) and the normal mammary epithelial cell line MCF12A, both of which have been used to study EMT and/or stem cell properties 3, 11 . By screening a genome-wide miRNA array, we identified miRNAs that have significant differences in expression levels between stem and non-stem cell populations in both cells lines (Supplementary Information, Table S1a), which were further validated using quantitative PCR (qPCR) analysis (Fig. 1a) . Among these miRNAs, miR-183 and miR-200c were the most downregulated in the stem cell population, compared with the non-stem cell population (> 2-fold change). Consistently, miR-183 and miR-200c were also identified as the most downregulated miRNAs in the stem cell population using a validated PCR array consisting of ~90 annotated miRNAs that are related to cancer and metastasis (SA Biosciences, data not shown). To further investigate the potential regulatory mechanism of these two miRNAs, we analysed the response elements of a group of transcription factors that are located within a 2 kb region upstream of the transcription start site of miR-183 and miR-200c using promoter analysis. Among all the transcription factor response elements, the p53 response element is present in both the miR-183 and miR-200c promoter regions with the highest consensus score of ≥ 0.98 for both miRNAs (matrix similarity score > 0.95 as cutoff, score = 1 as perfect match; Fig. 1b and Supplementary Table S2a, b). To validate direct association of p53 with miR-200c and miR-183 promoters, we performed chromatin immunoprecipitation (ChIP) analysis in HMEC cells for all the putative p53-consensus-binding elements within miR-200c and miR-183 promoters (Fig. 1b, elements A-E) using an antibody specifically against p53. The ChIP results revealed that p53 is most significantly bound to element C within the miR-200c promoter and element E within the miR-183 promoter (Fig. 1c) . Knockdown of p53 diminished the amount of DNA (element C and E) that could be immunoprecipitated by p53 antibody (Fig. 1d) , suggesting p53 directly and specifically associates with these promoter regions. Cells expressing luciferase reporters driven by miR200c and miR-183 promoters (Fig. 1b) were treated with etoposide to upregulate p53. This resulted in transcriptional activation of luciferase, which was impaired by mutations of the p53 response elements (C and E; Fig. 1e ). Consistently, ectopic expression of p53 in both HMEC and MCF12A cells significantly increased expression of miR-200c and miR-183 in both cell lines (Fig. 1f) . miR-200b was used as a negative control as it was not regulated by p53 (Fig. 1f and Supplementary Table S1b) . Furthermore, knockdown of p53 markedly reduced levels of miR-200c and miR-183 ( Fig. 1g and Supplementary Table S1 ) and increased the mRNA levels of KLF4 and BMI1, two stemness-associated genes that are known RNA targets of miR-200c and miR-183 (ref. 4 ; Fig. 1g ). These data suggest that p53 binds to specific promoter elements of miR-200c and miR-183, and activates transcription. Given the association of certain miRNAs, such as miR-183 and miR-200c, with EMT and stem cell properties in previous studies 3, 4 , we reasoned that p53 may have a role in regulating EMT plasticity and stem cell properties through regulation of these miRNAs. To test this hypothesis, we first examined p53 and EMT marker expression levels during EMT. We treated MCF12A cells with TGF-β for 7 days, a standard treatment that induces EMT 3 . Similarly to previous observations, TGF-β treatment induced an EMT phenotype from a cobblestone-like to a spindle-like morphology ( Supplementary Fig. S1a ), accompanied by decreased expression of E-cadherin ( Supplementary Fig. S1b ). Interestingly, p53 expression level was also significantly reduced during TGF-β-induced EMT ( Supplementary Fig. S1b ). Next, we investigated whether expression levels of the p53-regulated miRNAs are also altered by TGF-β treatment. We found that similarly to p53, miR-183 and miR-200c are downregulated, whereas two of the RNA targets of miR-200c and miR-183-BMI1 and KLF4-are upregulated in TGFβ-induced EMT cells ( Supplementary Fig. S1c ). Compared with miR-183, miR-200c has a more significant response to TGF-β treatment ( Supplementary  Fig. S1c ), so we therefore focussed on miR-200c as the prime target of p53 regulation. Together, these data suggest that p53 expression physiologically associates with miRNAs that are involved in the regulation of EMT and stem cell properties. To understand whether p53 can directly regulate EMT and EMTassociated stem cell properties, we first knocked down p53 in MCF12A cells using three individual shRNAs ( Fig. 2 and Supplementary Fig. S1d-f ). Similarly to TGF-β treatment ( Supplementary Fig. S1a-c) , reduction of p53 expression converted the predominant epithelial phenotype to an EMT phenotype (Fig. 2a) , accompanied by a decrease of epithelial cell marker, such as E-cadherin, and an increase of mesenchymal cell markers, such as N-cadherin, Vimentin and ZEB1 ( Fig.2b and Supplementary  Fig. S1d, e) . Next, we investigated whether increased expression of p53 could revert the mesenchymal phenotype to an epithelial phenotype (MET). We expressed p53-GFP in TGF-β-treated MCF12A cells and examined E-cadherin expression in the isolated GFP + cell populations. Both p53 and E-cadherin were downregulated on TGF-β treatment ( Supplementary Fig. S1a, b) . Here, we found that enhanced p53 expression by ectopic expression (Supplementary Fig. S2a ) or by etoposide treatment ( Supplementary Fig. S2c ) is able to revert TGF-β-induced mesenchymal phenotype to an epithelial phenotype ( Supplementary  Fig. S2b ), and block E-cadherin suppression mediated by TGF-β treatment ( Supplementary Fig. S2a and S2d). Consistently, in an established HMEC-Snail cell line 3 that shows predominant mesenchymal phenotype, re-expression of p53 led to significant elevation of E-cadherin expression (Fig. 2c) . These data suggest that p53 may regulate EMT-MET plasticity.
To elucidate whether p53 could also influence EMT-associated stem cell properties, we knocked-down p53 in MCF12A cells. Consistent with the previous results showing loss of epithelial phenotype by knockdown of p53 (Fig. 2a) , reduced p53 expression resulted in significant elevation of the CD24 -
CD44
+ stem cell population ( Fig. 2d and Supplementary Fig. S1f ) and enhanced BMI1 expression ( Fig. 2b and Supplementary Fig. S1e ). To determine whether increased expression of p53 could repress stem cell population enhanced by TGF-β treatment, we expressed p53-GFP in TGF-β-treated MCF12A cells and examined abundance of the CD24 -CD44 + stem cell population in the isolated GFP + cell populations ( Supplementary Fig. S3a ). Indeed, p53 expression blocked the increase of stem cell population induced by TGF-β treatment ( Supplementary Fig. S3a ). Furthermore, in HMECSnail cells, which showed high abundance of the CD24 -CD44 + stem cell population, re-expression of p53 also significantly decreased CD24 -CD44 + cells (Fig. 2e) . These data suggest that p53 may suppress EMT-associated stem cell properties.
To further understand whether p53 regulates EMT-MET transition by modulating miR-200c, we expressed precursor miR-200c in MCF12A cells with p53 knockdown. Re-expression of miR-200c significantly diminished ZEB1, KLF4 and BMI1 expression, but restored E-cadherin expression, which was repressed by knockdown of p53 (Fig. 3a) . These results indicated that p53 may modulate EMT by upregulating miR-200c. Re-expression of miR-200c also significantly diminished the percentage of CD24 -CD44 + cells ( Fig. 3b ) and formation of mammospheres ( Fig. 3c) , both of which were enhanced by knockdown of p53 (Fig. 3b, c) . Similarly, to further examine if inhibiting miR-200c could rescue the effects of expressing p53, we applied miR-200c-antagomiR in HMEC-Snail cells expressing p53. miR200c-antagomiR counteracts the effects of expressing p53 as it reduced the level of the epithelial cell marker E-cadherin that was increased by p53 expression (Fig. 3d ). miR200c-antagomiR also restored expression levels of ZEB1, BMI1 and KLF4 (Fig. 3e ) and enhanced the CD24 -CD44 + population ( Fig. 3f ), all of which were diminished by p53 expression (Fig. 3e, f) . Taken together, these observations indicate that p53 regulates EMT and stemness through the regulation of miR-200c. As p53 is an essential tumour suppressor and EMT-stemness has also been implicated as an important component during tumorigenesis, we investigated the role of p53-miR200c regulation in human cancer cells. First, we overexpressed p53 mutants that were previously identified from various breast cancer samples 6 in a normal MCF12A cell line. We found that, in contrast to the effects of expressing wildtype p53 (Fig. 4a, left) , expression of these p53 mutants increased ZEB1, N-Cadherin and BMI1 levels (Fig. 4a, right) , led to decreased miR-200c expression (Fig. 4b) , and also enhanced CD24 -CD44 + cell population (Fig. 4c) . To examine whether the decrease in miR-200c by overexpression of mutated p53 is caused by impaired binding of p53 to the miR-200c promoter, we performed a ChIP assay using a p53 antibody that recognizes both wild-type p53 and mutated p53. Overexpression of mutated p53 significantly inhibited bound p53 on the miR-200c promoter (Fig. 4d) . Furthermore, consistent with the results of expressing p53 in normal cell lines, overexpression of wildtype p53 in breast cancer cell line BT549 (harbouring a p53 R249S mutant) increased miR-200c and decreased ZEB1 and BMI1 levels ( Fig. 4e, f) . However, knockdown of mutated p53 did not alter expression of either miR-200c, ZEB1 or BMI1 in BT549 cells (Fig. 4e, f) . These data suggest that it is the wild-type p53, not the mutated p53, that upregulates miR-200c. Together, our results suggest that mutated p53 could interfere with wild-type p53 activity as indicated by previous studies [7] [8] [9] and thereby counteracts wild-type p53-mediated regulation on ZEB1 and BMI1 expression through modulation of miR-200c. However, overexpression or activation of wild-type p53 in cancer cell lines may override the mutated p53 (ref. 10 ) and enforce the promotion of miR-200c to block EMT and stem cell properties.
To provide physiological evidence for p53 regulation of EMT and stem cell properties, we collected mammary tissues from two p53 knockout mice and their wild-type counterparts (Fig. 5a ). Consistent with our observations of knocking down p53 in human mammary epithelial cells, mouse mammary cells with p53 knockout exhibited elevated expression of N-cadherin, ZEB1 and BMI1 (Fig. 5b) , and ZEB1 and BMI1 mRNA (Fig. 5c) , along with significant reduction of miR-200c level (Fig. 5c ), compared with wild type. To further strengthen the pathological correlation between p53 and EMT-stem cell-associated markers in breast cancer, we performed a correlation analysis of p53, ZEB1, E-cadherin and BMI1 protein expression levels and miR-200c miRNA level using immunohistochemistry and in situ hybridization, respectively, in breast cancer tissue microarrays consisting of 106 breast tumour samples (Fig. 5d, e) . Consistently, loss of p53 correlated positively with increased ZEB1 and BMI1 expression levels, but negatively with miR-200c and E-cadherin levels ( Fig. 5d, e) . Loss of p53 also correlated positively with poor differentiation in high grade tumours (Fig. 5f ) in which miR-200c expression level was significantly reduced when compared with the well-differentiated tumours (Fig. 5f ). These data suggest loss of p53 could lead to downregulation of miR-200c and activation of EMT and stemness signature that contribute to breast cancer progression. In this study, we first used promoter analysis and miRNA array profiling to identify a link between p53 and miRNAs in the regulation of both EMT and stem cell properties. Furthermore, physiological induction of EMT, for example by TGF-β treatment, could inhibit p53 expression by increasing MDM2 (ref. 11). Alternatively, TGF-β could activate downstream ZEB1 transcription suppressors that repress the epithelial regulator E-cadherin and miR-200c, leading to initiation of the EMT programme ( Supplementary Fig. S1a-c) . Activation of p53 and its transcriptional target miR-200c led to MET and differentiation phenotype as a result of restored E-cadherin expression and repressed stemnessassociated BMI1 expression (Fig. 5g) . In tumour cells deficient in p53 or with constitutively active TGF-β signalling, the miR-200c targets BMI1 and KLF4 are constitutively activated to maintain stemness and generate a stem cell-like population (Fig. 5g) . However, this process can be reversed in normal cells as we found that on removal of TGF-β from MCF12A cells pre-treated with TGF-β for 14 days, p53 expression level was readily restored in 4 days, accompanied by markedly increased expression of epithelial marker E-cadherin and reduced CD24 -CD44
+ stem cell population ( Supplementary Fig. S3b ). It is known that EMT has an essential role in cancer metastasis, and that restoration of the MET programme should efficiently slow dissemination of tumour cells 5 . Many molecules have been shown to mediate EMT, but the regulators that contribute to MET, especially in adult normal or neoplastic epithelial models, remain to be elucidated. From our results, p53 overexpression in HMEC-Snail cells reverts the mesenchymal phenotype to the epithelial phenotype ( Supplementary  Fig. S4a ), without inducing significant effects in cell senescence, cell death or cell cycle regulation ( Supplementary Fig. S4a and S4b). Our study suggests that p53 has a role in regulating EMT-MET plasticity, and potentially is involved in cancer metastasis as a safeguard for maintaining differentiated epithelial cell phenotype independent of its conventional function.
Furthermore, stemness properties of normal stem cells are often shared with stem-like cells within tumours termed 'tumour initiating cells' (TICs). These TICs are shown to account for tumour initiation, progression and chemo-resistance 12 . Thus, our results suggest that the p53-miR-200c pathway most likely accounts for regulating the 
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The authors declare no competing financial interests. Plasmid construction. Retroviral contructs pMKO.1-puro-p53 shRNAs, lentiviral constructs which direct the expression of wild-type p53 (pLenti6-V5-p53_ wt p53), p53 mutants (pLenti6-V5-p53R175H, pLenti6/V5-p53R249S, pLenti6-V5-p53R273H and pLenti6-V5-p53R280K) 6 and shRNA against p53 (pLKO-p53-shRNA-427 and pLKO-p53-shRNA-941) 13 and their control vectors were purchased from Addgene. To obtain the luciferase constructs miR-183-Luc or miR-200C-Luc, a PCR-derived fragment from the miR-200c or miR-183 promoters was inserted into XhoI-and HindIII-treated pGL3 vector (Promega). To generate mutated miR-183-Luc or miR-200c-Luc construct that harbour mutations in the putative p53 response elements, a PCR-based site-directed mutagenesis (Stratagene) was used. The retroviral expression vector pBMN-p53 was constructed by inserting an EcoRI-SalI-treated fragment of the p53 gene derived by reverse transcription PCR (RT-PCR) into EcoRI-XhoI-treated pBMN-I-GFP vector (purchased from Addgene). All of these constructs were verified by DNA sequencing.
Promoter analysis. Analysis of putative transcription factor binding sites on miR-183 and miR-200c promoter was done by TRED (Cold Spring Harbor Laboratory) and Genomatix software. + (non-stem) cell populations isolated from primary human mammary epithelial cells (HMECs) and normal mammary epithelial cell line (MCF12A) using flow cytometry. Total RNA was prepared using RNeasy Plus Mini kit (Qiagen) following the manufacturer's protocol. Target labelling, hybridization, imaging and data processing were performed by genomic facility at MD Anderson Cancer Center using miRCURY LNA microRNA Array, 5th generation platform (Exiqon).
Generation of stable p53-expressed and knocked-down cell lines. For retroviral infection, Phoenix-Ampho cells (Allele Biotechnology) were used for virus package according to the manufacturer's instructions. Briefly, retroviral constructs, such as pMKO.1-puro-p53shRNAs or pBMN-p53, were transfected into Phoenix-Ampho cells, and viral particles were harvested at 24 and 48 h post-transfection. HMEC or MCF12A cells were infected with virus for 24 h twice in the presence of polybrene (5 μg ml -1 ). To obtain the p53-shRNA knockdown cell line or the control cell line, MCF12A cells infected with pMKO.1-puro-p53shRNA (p53 shRNA: 5ʹ-GACTCCAGTGGTAATCTACTG-3ʹ) or control vectors were subsequently selected with puromycin (2 μg ml -1 ) for 2 weeks, and the expression of p53 was examined by western blotting. For lentiviral infection, the third generation lentivirus packaging system was used 14 . Briefly, lentiviral construct that expresses wild-type p53, p53 mutants or shRNAs targeting p53 (p53 shRNA-1: 5ʹ-CACCATCCACTACAACTACAT-3ʹ; p53 shRNA-2: 5ʹ-GTCCAGATGAAGCTCCCAGAA-3ʹ) were co-transfected with lentiviral packaging plasmids pMDLg-pRRE, PRSV-Rev or PMD2G into 293T cells by ChIP assay. Chromatin immunoprecipitation experiment was modified from the EZ-CHIP (Upstate) protocol using p53 antibody (Santa Cruz). Primer sequences used were as described 15 .
Luciferase reporter assay. Cells were transfected with reporter plasmid, miR-183-Luc or miR-200c-Luc, and the TK-Renilla reporter (Promega) was also co-transfected for normalization of transfection efficiency. Transfected cells were treated with etoposide (Sigma) and harvested at 48 h post-transfection, and a dual luciferase assay was performed according to the manufacturer's instructions (Promega). The luciferase activity was measured with an AutoLumat LB953 luminometer (Berthold).
Real-time PCR. Total RNAs were extracted from cells by using RNeasy kit (Qiagen). RNAs were reverse-transcribed by using Superscript II kit (Invitrogen). The results were analysed by the iCycler (Biorad), and the quantification of RNA levels was normalized to GAPDH as CT (difference of cycling threshold) = CT (target) -CT (control). Higher CT values indicate relatively lower expression of RNA. Primer sequences were used as follows: p53 Exon2, 5ʹ-CATCACCTCACTGCATGGAC-3ʹ (forward); p53Exon2, 5ʹ-AAGCCATAGTTGCCCTGGTA-3ʹ (reverse), and also were as previously described 4 .
Senescence assay. Cell senescence was measured by β-Galactosidase Staining kit (Cell Signaling) according to the manufacturer's instructions.
Antibodies.
The following antibodies were purchased commercially: anti-ZEB1 (1:1,000; D80D3, Cell signaling Tech.), anti-p53 (1:1,000; DO-1, Santa Cruz), anti-E-Cadherin (1:500; Santa Cruz), anti-N-cadherin (1:1,000; Ab76057, Abcam), anti-Vimentin (1:1,000; Santa Cruz), anti-BMI1 (1:2,000; Bethyl Laboratories), FITC-conjugated anti-CD44 (1:40; BD Biosciences), APC-conjugated anti-CD44 (1:40; BD Biosciences), PE-conjugated anti-CD24 (1:40; BD Biosciences), and PerCP-Cy5.5 anti-Human CD324 (E-Cadherin, Biolegend). p53 knockout mice. Mammary tissues were dissected from p53 knockout mice and the wild-type counterparts (gifts from E. Flores; MD Anderson Cancer Center, USA). Information on the p53-knockout mice was as described 16 . p53 deletion was validated by detecting p53 Exon2 mRNA expression using RT-PCR.
Tissue microarray. Breast cancer tissue microarrays (BRC1021, Fig. 5e ; BRC1502 and BRC1503, Fig. 5f ) were purchased from Pantomics. Each array includes more than 100 cases of normal, reactive, premalignant and malignant tissues of the breast (various grades and stages).
Immunocytochemistry and in situ hybridization. Immunohistochemical staining was performed as previously described 17 using anti-p53 antibody that preferentially recognizes wild-type p53 (1:40; PAb1620, Calbiochem) [18] [19] [20] , anti-BMI1 (1:40; R&D Systems), anti-ZEB1 (1:100; Bethyl Laboratories) and anti-E-cadherin (1:100; Cell Signaling). In situ hybridization was performed using an miRNA-200c probe from Exiqon (miRCURY LNA detection probe 5ʹ-DIG (digoxigenin)-labelled). Detection of the probe was carried out using digoxigenin antibody (21H8; 1:200, ab420, Abcam), LSAB2 System-HRP (K0672, Dako) and liquid DAB+ Substrate Chromogen System (K3468, Dako) according to the manufacturer's instructions. The correlation between p53 and ZEB1, BMI1, E-cadherin and miR-200c was analysed using Chi-Square test.
Statistical analysis. All data were presented as means ± s.d. Statistical calculations were performed with Microsoft Excel analysis tools. Differences between individual groups were analysed by paired t test. P values of < 0.05 are considered statistically significant.
Accession Numbers.
MicroRNA array data is deposited in NCBI GEO database (GSE 25037). In the version of this article initially published online and in print, Figs 2b and 4a contained panels that did not match those in Supplementary Fig.  S5 , which showed full uncropped scans corresponding to the specific figures. In Fig. 2b , the p53 panel was stretched so that the image was thinner than that shown in Supplementary Fig. S5 . The p53 image was inadvertently duplicated and shown in place of the correct E-cadherin panel. The N-cadherin panel was derived from an independent experiment, and not the scan shown in Supplementary Fig S5. Finally, the actin panel was stretched and reversed, compared with Supplementary Fig. S5 . The correct images are shown below. In the image shown below, the N-cadherin panel now corresponds to the scan shown in Supplementary Fig. S5 . In Fig. 4a of the original manuscript, the image of the gel was reversed, and when cropped the incorrect bands were then shown in Fig. 4a and Supplementary Fig. S5 (the correct image was shown in Supplementary Fig. S1d, however) . The amended image for Fig. 4a and Supplementary Fig. S5 are shown below. The red line in the uncropped scan shown below indicates where the scan was cropped; lanes 1-5 are now shown in Fig. 4a , and lanes 6-8 were shown in Supplementary Fig.  S1d in the original manuscript.
We apologize for these serious mistakes. The original conclusions of the paper are unchanged. Table S2b Predicted consensus transcritption factor binding sites in miR-200b promoter <2kb upstream (Score>0.95)
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